NovacytLSE:NCYT -2.11%39 Quick Ratio is 4.32 as of Dec. 2025, which is 67% above its 10-year median of 2.59. GuruFocus rates LSE:NCYT with a GF Score™ of 39/100 and a GF Value™ of £0.59 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Novacyt ranks better than 78.9% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Novacyt's quick ratio for the quarter that ended in Dec. 2025 was 4.32.
Novacyt has a quick ratio of 4.32. It generally indicates good short-term financial strength.
The historical rank and industry rank for Novacyt's Quick Ratio or its related term are showing as below:
LSE:NCYT'
s Quick Ratio Range Over the Past 10 Years
Min: 0.65 Med: 2.59 Max: 5.97
Current: 4.32
During the past 13 years, Novacyt's highest Quick Ratio was 5.97. The lowest was 0.65. And the median was 2.59.
LSE:NCYT's Quick Ratio is ranked better than 78.9% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 1.89
vs LSE:NCYT: 4.32
Novacyt (LSE:NCYT) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Novacyt Quick Ratio Related Terms
Novacyt Quick Ratio Historical Data
* Premium members only.
The historical data trend for Novacyt's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Novacyt's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novacyt Quick Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Novacyt's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Novacyt's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Novacyt's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novacyt (LSE:NCYT) has a Quick Ratio of 4.32 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Novacyt and its competitors. This is 67% above median its historical median of 2.59. Over the past decade, Novacyt's Quick Ratio has ranged from 0.65 to 5.97. According to the industry distribution chart, Novacyt ranks #180 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 21.1%.
Is Novacyt's Quick Ratio too high?
Novacyt's current Quick Ratio of 4.32 is 67% above median its 10-year median of 2.59. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 5.97. The Medical Devices & Instruments industry median Quick Ratio is 1.89. Novacyt's value of 4.32 is 128.6% above this industry median. Based on the distribution chart, Novacyt ranks #180 out of 853 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Novacyt has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Novacyt's Quick Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Novacyt ranks #180 out of 853 companies for Quick Ratio. This places Novacyt in the top 21% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.89. Novacyt's value of 4.32 is 128.6% above this benchmark. Historically, Novacyt's own Quick Ratio has ranged from 0.65 to 5.97 over the past decade. While the company's 10-year median is 2.59 vs. the industry median of 1.89, Novacyt has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Medical Devices & Instruments company?
The median Quick Ratio among Medical Devices & Instruments companies is 1.89, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novacyt's current Quick Ratio of 4.32 is 128.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Novacyt and its competitors. For the Medical Devices & Instruments industry, the median Quick Ratio is 1.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novacyt's current Quick Ratio is 4.32, which is 67% above median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novacyt stock overvalued right now?
Based on GuruFocus' analysis, Novacyt (LSE:NCYT) is currently considered Possible Value Trap. The stock's GF Value™ is £0.59, compared to a current price of £0.35 — trading 41.1% below its estimated fair value. The current Quick Ratio is 4.32, which is 67% above median its 10-year median of 2.59 and 128.6% above the Medical Devices & Instruments industry median of 1.89. Novacyt's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Novacyt (LSE:NCYT), the current Quick Ratio is 4.32 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novacyt (LSE:NCYT) Overvalued in 2026?
Based on GuruFocus' analysis, Novacyt stock appears to be undervalued.
The current stock price of £0.35 is trading 41.1% below its estimated GF Value™ of £0.59.
GuruFocus considers Novacyt to be Possible Value Trap.
Key valuation signals for LSE:NCYT:
Quick Ratio: 4.32 (67% above median its 10-year median of 2.59)
GF Value™: £0.59 vs. price of £0.35 (41.1% below fair value)
Industry Position: 128.6% above the Medical Devices & Instruments median (#180 of 853)
No single metric tells the full story. See the LSE:NCYT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments: Primer Design, Yourgene Health and Corporate. Majority of the revenue is generated from Yourgene Health segment. Geographically, the company operates in United Kingdom, France, Europe, America, Asia-Pacific, Middle East and Africa generating majority from Asia- pacific region.
39GF Score
Get the complete analysis for LSE:NCYT
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:NCYT has been successfully added to your 
